Tohru Takeuchi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2425950/publications.pdf

Version: 2024-02-01

all docs

60 874 15 26 papers citations h-index g-index

times ranked

citing authors

docs citations

#	Article	IF	CITATIONS
1	The addition of iguratimod can reduce methotrexate dose in rheumatoid arthritis with clinical remission. Modern Rheumatology, 2022, 32, 68-73.	1.8	O
2	Comparison of therapeutic effects of combination therapy with prednisolone and tacrolimus or azathioprine on progressive interstitial pneumonia with systemic sclerosis. Modern Rheumatology, 2022, 32, 358-364.	1.8	10
3	Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Scientific Reports, 2022, 12, 134.	3.3	18
4	Combination of immunosuppressive therapy and nintedanib improves capillaroscopic changes in systemic sclerosis-interstitial lung disease: a case report. Rheumatology Advances in Practice, 2022, 6, rkac003.	0.7	2
5	Comment on: Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation–associated gene 5–positive dermatomyositis. Rheumatology, 2022, , .	1.9	1
6	Comment on: Combination of immunosuppressive therapy and nintedanib improves capillaroscopic changes in systemic sclerosis-interstitial lung disease: a case report. Reply. Rheumatology Advances in Practice, 2022, 6, rkac025.	0.7	0
7	Comment on: Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD. Rheumatology, 2022, , .	1.9	O
8	Association of M2 Macrophages, Th2, and B Cells With Pathomechanism in Microscopic Polyangiitis Complicated by Interstitial Lung Disease. Journal of Rheumatology, 2022, 49, 913-921.	2.0	1
9	Simplified disease activity index and clinical disease activity index before and during pregnancy correlate with those at postpartum in patients with rheumatoid arthritis. Modern Rheumatology, 2021, 31, 809-816.	1.8	5
10	Evaluation of poor prognostic factors of respiratory related death in microscopic polyangiitis complicated by interstitial lung disease. Scientific Reports, 2021, 11, 1490.	3.3	13
11	Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study. Clinical Rheumatology, 2021, 40, 2673-2680.	2.2	13
12	Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study. Archives of Osteoporosis, 2021, 16, 39.	2.4	4
13	Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis—the ANSWER cohort study. Arthritis Research and Therapy, 2021, 23, 116.	3.5	16
14	Pre-pregnancy serum complement C3 level is a predictor of preterm birth for pregnancies with systemic lupus erythematosus. Arthritis Research and Therapy, 2021, 23, 140.	3.5	8
15	2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respiratory Investigation, 2021, 59, 709-740.	1.8	45
16	Initial serum GM-CSF levels are associated with the severity of cerebral small vessel disease in microscopic polyangiitis patients. Journal of Neuroimmunology, 2021, 359, 577671.	2.3	1
17	Comment on: Nailfold capillaries and myositis specific antibodies in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis. Rheumatology, 2021, , .	1.9	O
18	Neuron-specific enolase level is a useful biomarker for distinguishing amyotrophic lateral sclerosis from cervical spondylotic myelopathy. Scientific Reports, 2021, 11, 22827.	3.3	4

#	Article	IF	CITATIONS
19	Low-Molecular-Weight Heparin Enhanced Therapeutic Effects of Human Adipose-Derived Stem Cell Administration in a Mouse Model of Lupus Nephritis. Frontiers in Immunology, 2021, 12, 792739.	4.8	O
20	The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort study. Rheumatology International, 2020, 40, 217-225.	3.0	3
21	Exploration of pathomechanism using comprehensive analysis of serum cytokines in polymyositis/dermatomyositis-interstitial lung disease. Rheumatology, 2020, 59, 310-318.	1.9	24
22	The comparison of nailfold videocapillaroscopy findings between anti-melanoma differentiation-associated gene 5 antibody and anti-aminoacyl tRNA synthetase antibody in patients with dermatomyositis complicated by interstitial lung disease. Scientific Reports, 2020, 10, 15692.	3.3	13
23	Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study. Rheumatology International, 2020, 40, 1987-1995.	3.0	11
24	Correlation of increased serum leucine-rich $\hat{l}\pm 2$ -glycoprotein levels with disease prognosis, progression, and activity of interstitial pneumonia in patients with dermatomyositis: A retrospective study. PLoS ONE, 2020, 15, e0234090.	2.5	7
25	Drug retention of 7 biologics and tofacitinib in biologics-na \tilde{A} -ve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study. Arthritis Research and Therapy, 2020, 22, 142.	3.5	24
26	Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study Clinical Rheumatology, 2020, 39, 2563-2572.	2.2	11
27	Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study PLoS ONE, 2019, 14, e0216624.	2.5	46
28	Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritisâ€"the ANSWER cohort study. Arthritis Research and Therapy, 2019, 21, 91.	3.5	36
29	Occurrence of cerebral small vessel disease at diagnosis of MPO-ANCA-associated vasculitis. Journal of Neurology, 2019, 266, 1708-1715.	3.6	6
30	THU0338â€SIMVASTATIN-CONJUGATED NANOPARTICLE ENHANCES THE THERAPEUTIC EFFECT OF ADIPOSE-DERIVED STEM CELLS ON INTERSTITIAL LUNG DISEASE. , 2019, , .		0
31	SAT0287â€SERUM CYTOKINE PROFILE IDENTIFIES PATHOMECHANISM AND EFFICIENT BIOMARKERS OF DISEA ACTIVITY AND PROGNOSIS IN INTERSTITIAL PNEUMONIA COMBINED WITH POLYMYOSITIS/DERMATOMYOSITIS., 2019,,.	SE	0
32	THU0350â€ANTI-INFLAMMATORY AND ANTI-FIBROTIC EFFECTS OF INTRAVENOUS ADIPOSE-DERIVED STEM CE TRANSPLANTATION IN A MOUSE MODEL OF BLEOMYCIN-INDUCED SCLERODERMA. , 2019, , .	ILL	0
33	Efficacy and safety of oral highâ€trough level tacrolimus in acute/subacute interstitial pneumonia with dermatomyositis. International Journal of Rheumatic Diseases, 2019, 22, 303-313.	1.9	11
34	Asymptomatic rheumatoid meningitis revealed by magnetic resonance imaging, followed by systemic rheumatic vasculitis: A case report and a review of the literature. Modern Rheumatology, 2019, 29, 370-376.	1.8	12
35	Potential of Krebs von den Lungenâ€6 as a predictor of relapse in interstitial pneumonia with antiâ€aminoacyl tRNA synthetase antibodiesâ€positive dermatomyositis. Clinical Respiratory Journal, 2018, 12, 2235-2241.	1.6	5
36	Efficacy and safety of combination therapy with prednisolone and oral tacrolimus for progressive interstitial pneumonia with systemic sclerosis: A retrospective study. Modern Rheumatology, 2018, 28, 1009-1015.	1.8	12

#	Article	IF	Citations
37	Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. Modern Rheumatology, 2018, 28, 133-140.	1.8	67
38	Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study. Modern Rheumatology, 2018, 28, 227-234.	1.8	19
39	Eosinophilic granulomatosis with polyangiitis complicated by subarachnoid hemorrhage and coronary vasculitis: a case report and review of the literature. Rheumatology International, 2018, 38, 689-696.	3.0	11
40	Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis. PLoS ONE, 2018, 13, e0202601.	2.5	12
41	Quantitative evaluation of human erythrocyte deformability by using a sheath flow micro-channel. The Proceedings of the Bioengineering Conference Annual Meeting of BED/JSME, 2018, 2018.30, 1F11.	0.0	0
42	Gastrointestinal involvement at the onset of granulomatosis with polyangiitis: A case report. Modern Rheumatology, 2017, 27, 162-164.	1.8	6
43	Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody. Rheumatology International, 2017, 37, 1335-1340.	3.0	29
44	Successful multiâ€ŧarget therapy including rituximab and mycophenolate mofetil in antiâ€melanoma differentiationâ€associated gene 5 antibodyâ€positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis. International Journal of Rheumatic Diseases, 2017, 20, 2182-2185.	1.9	21
45	Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study. Scientific Reports, 2017, 7, 1635.	3.3	23
46	Initial limited three-level thin-section computed tomography scorings predict the prognosis of acute/subacute interstitial pneumonia in patients with dermatomyositis. Modern Rheumatology, 2016, 26, 738-743.	1.8	12
47	Differentiation between Polymyalgia Rheumatica (PMR) and Elderly-Onset Rheumatoid Arthritis Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Is Enthesitis a New Pathological Lesion in PMR?. PLoS ONE, 2016, 11, e0158509.	2.5	50
48	Periodontal pathogens participate in synovitis in patients with rheumatoid arthritis in clinical remission: a retrospective case–control study. Rheumatology, 2015, 54, kev274.	1.9	7
49	Increased Serum LIGHT Levels Correlate with Disease Progression and Severity of Interstitial Pneumonia in Patients with Dermatomyositis: A Case Control Study. PLoS ONE, 2015, 10, e0140117.	2.5	7
50	Pre-Treatment Ferritin Level and Alveolar-Arterial Oxygen Gradient Can Predict Mortality Rate Due to Acute/Subacute Interstitial Pneumonia in Dermatomyositis Treated by Cyclosporine A/Glucocorticosteroid Combination Therapy: A Case Control Study. PLoS ONE, 2014, 9, e89610.	2.5	39
51	Good response to infliximab in a patient with deep vein thrombosis associated with Behçet disease. Modern Rheumatology, 2012, 22, 791-795.	1.8	18
52	Successful treatment with tocilizumab of pericarditis associated with rheumatoid arthritis. Modern Rheumatology, 2012, , 1.	1.8	1
53	Therapeutic drug monitoring of cyclosporine microemulsion in interstitial pneumonia with dermatomyositis. Modern Rheumatology, 2011, 21, 32-36.	1.8	16
54	FDG-PET/CT of polymyalgia rheumatica. Modern Rheumatology, 2011, 21, 334-336.	1.8	8

Tohru Takeuchi

#	Article	IF	CITATION
55	Successful treatment of thrombotic thrombocytopenic purpura with repeated plasma exchange in a patient with microscopic polyangitis. Modern Rheumatology, 2008, 18, 643-646.	1.8	16
56	Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. Journal of Rheumatology, 2008, 35, 254-9.	2.0	68
57	Serum protein profile of rheumatoid arthritis treated with anti-TNF therapy (infliximab). Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 855, 66-70.	2.3	11
58	Eosinophilic peroxidase deficiency: Identification of a point mutation (D648N) and prediction of structural changes. Human Mutation, 2001, 17, 235-236.	2.5	11
59	Functional Defect of B Lymphocytes in a Patient with Selective IgM Deficiency Associated with Systemic Lupus Erythematosus. Autoimmunity, 2001, 34, 115-122.	2.6	40
60	A Novel Mutation in the $Fc\hat{1}^3$ RIIIA Gene (CD16) Results in Active Natural Killer Cells Lacking CD16. Autoimmunity, 1999, 31, 265-271.	2.6	9